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OBJECTIVES: Clinical trials demonstrated beneﬁts of
HMG-CoA inhibitors (statins) use only after long-term
continuous treatment. However, real-world treatment
compliance treatment is sub-optimal. This study describes
the patterns and risk factors associated with discontinu-
ation in a managed care population. METHODS: Retro-
spective claims from a large California-based managed
care organization were retrieved between December 1997
and June 2000. A total of 25,854 adult patients were
identiﬁed as new statin users during a 1-year identiﬁca-
tion period (with 6 month run-in period, and a null reﬁll
indicator on index date). Discontinuation was deﬁned as
the ﬁrst occurrence when a gap between current ﬁll date
and the last day of the expected supply is greater than 30
days. Medication possession ratios (MPR) were calcu-
lated from index date to the end of each month up to 
one year. Survival analysis was applied to study the risk
factors associated with early discontinuation. Patient
demographics, payer type, previous drug and medical 
utilization, comorbidities, and other risk factors are con-
trolled in the regressions. RESULTS: MPRs were plotted
against time horizon, and the ratios declined faster than
a log-linear fashion, dropping from 74% by month 3 to
57.5% by month 12. By the end of the ﬁrst year, 43.5%
patients have experienced discontinuation. Cox propor-
tional hazard regression revealed that patients initiated
with lovastatin (hazard ratio, HR = 1.39) and simvastatin
(HR = 1.13) are signiﬁcantly more likely to discontinue
than patients on atorvastatin. Patients with FFS plan 
type associated with lower risk of noncompliance than
managed care patients (PPO, POS, HMO). Comorbidity
indicators were unrelated to compliance pattern. Some
types of previous medication use, including ﬁbric acid
derivatives, beta-blocker, antihypertensives, and diuretics,
were associated with higher compliance rate. Patients
who had recent CABG or PTCA tended to have higher
compliance (HR = 0.86, p = 0.02). CONCLUSIONS:
The compliance measured by medication possession ratio
declined rapidly over time. Statin of initial choice (ator-
vastatin), FFS plan type, previous use of other medica-
tions, and previous surgery (CABG/PTCA) were strongly
associated with medication adherence.
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CHOLESTEROL GOAL ATTAINMENT IN
PATIENTS WITH DIABETES: EVIDENCE FROM
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OBJECTIVES: Patients with diabetes are at high risk for
coronary heart disease (CHD) and tight control of lipid
levels is an important clinical objective. In this study, 
we assessed the rate of cholesterol goal attainment 
among patients with diabetes in a managed care setting.
METHODS: A retrospective cohort design was employed
using linked pharmacy, medical, and clinical laboratory
data from members of a Northeastern US group model
HMO. The study cohort included diabetes patients 55+
years of age without CHD who began lipid-lowering drug
therapy between 1995 and 1998. Patients were required
to have had an LDL-C value over 160mg/dL within 90
days before beginning treatment. The change in LDL-C
and the rate of NCEP ATP II goal attainment (LDL <
130mg/dL) were evaluated over 1 year. RESULTS: A total
of 318 patients met study eligibility criteria. The average
age was 68 years and 43% were male. The mean base-
line LDL-C level was 195mg/dL (±28mg/dL) and about
52% of patients had a baseline LDL-C level of 160-189
mg/dL. Ninety-four percent (n = 298) of patients had ≥1
follow-up LDL-C measurements during follow up. The
mean decline in LDL-C was 22% (±14%). The ATP II
treatment goal was reached by 36% of patients. About
50% of patients with baseline LDL-C of 160-189mg/dL
achieved goal versus 21% of patients ≥190mg/dL. Better
adherence to treatment (≥50% of days covered) and more
frequent monitoring of lipid levels were both positively
associated with goal attainment. CONCLUSIONS: In the
mid-to-late 1990s, most patients with diabetes treated for
hyperlipidemia did not achieve their cholesterol goals.
Recent guidelines (NCEP ATP III) have identiﬁed diabetes
patients as a “CHD risk equivalent” with a lower 
cholesterol goal (LDL < 100mg/dL). Further research is
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warranted to identify steps for increasing treatment 
effectiveness in these patients.
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INFLUENCE OF DIABETES AND BASELINE ST-
SEGMENT CHANGE STATUS ON THE COST-
EFFECTIVENESS OF AN EARLY INVASIVE VS.
CONSERVATIVE STRATEGY FOR THE
TREATMENT OF ACUTE CORONARY
SYNDROMES:APPLICATION OF A NET-BENEFIT
REGRESSION APPROACH TO DATA FROM THE
TACTICS-TIMI 18 TRIAL
Mahoney EM1, Chu H1, Jurkovitz CT1, Cannon CP2,
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OBJECTIVES: Prior results from the TACTICS-TIMI 
18 trial demonstrated that an early invasive approach 
to the management of patients with unstable angina 
(UA) or non-ST-segment elevation myocardial infarction
(NSTEMI) was cost-effective, with an estimated cost per
life-year gained of $8371; for high-risk patients with ST-
segment changes at baseline, $3224 per life-year gained.
We examined the joint inﬂuence of diabetes and ST-
segment changes on the cost-effectiveness of the early
invasive strategy. METHODS: Inpatient hospital costs for
the 1722 US, non-VA patients for the 6-month trial
period were obtained from the UB92 and Medicare
cost/charge ratios. Other costs included: physician, 
outpatient, medication, and productivity costs. Life-
expectancy estimates for patients with acute MI/coronary
heart disease from the Framingham Heart Study were
used for patients who survived the trial with/without
experiencing a non-fatal MI. Cost-effectiveness was eval-
uated in terms of cost per life-year gained. Regression
analyses of the net monetary beneﬁt across a range of
ceiling ratios were used to obtain cost-effectiveness
acceptability curves for subgroups deﬁned by diabetes
and ST-change status. RESULTS: Net monetary beneﬁt
regression analyses revealed a three-way interaction
between diabetes, ST-changes and treatment group which
approached signiﬁcance (p < 0.10) for models based on a
ceiling ratio of $14,000–$49,000. Associated cost-
effectiveness acceptability curves suggest a probability
that the invasive strategy is cost-effective for non-diabetic
patients with ST-segment changes of >95% for ceiling
ratios $4000 per life-year gained. At a ceiling ratio of
$50,000, the probability of cost-effectiveness for diabetic
patients without ST-changes is 56%, for diabetic patients
with ST-changes, 73%, and for non-diabetic patients
without ST-changes, 74%. CONCLUSIONS: In addi-
tion to ST-segment changes at presentation, the cost-
effectiveness of an invasive strategy for patients with UA
or NSTEMI varies by DM status. This analysis demon-
strates the usefulness and efﬁciency of net-beneﬁt regres-
sion for the evaluation of cost-effectiveness for different
patient subgroups.
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EFFECTIVENESS OF AMLODIPINE VS.
VALSARTAN UPON BLOOD PRESSURE CHANGE
AND CONTROL AMONG HYPERTENSIVE
ADULTS
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OBJECTIVES: To compare the effectiveness of two
widely prescribed agents, amlodipine and valsartan, in
blood pressure lowering and control in a multi-center
ambulatory practice setting. METHODS: All adult hyper-
tensive patients were identiﬁed from 1998 to 2001 from
a large commercially available electronic medical record
covering over 360,000 US primary care patients. Study
patients were required to have initiated therapy with
either amlodipine or valsartan and to have at least one
BP measurement within 6 months preceding and 12
months following the index date. Mean change in systolic
blood pressure (SBP) and rates of JNC VI BP goal 
attainment were compared using multivariate statistics.
RESULTS: One thousand one hundred seventy-ﬁve
amlodipine and 512 valsartan patients met criteria. Base-
line SBP was 159.5mmHg for amlodipine; 159.9 for 
valsartan. Overall, amlodipine was associated with 
an adjusted mean change of -16.6mmHg in SBP (95%
CI-17.7, -15.5) vs. -13.4mmHg for valsartan (95% 
CI-15.1, -11.7; p = 0.002). Approximately 43% of
amlodipine patients achieved JNC VI goal vs. 33% in the
valsartan treated cohort (p = 0.030). Among patients on
complex antihypertensive regimens (2 or more agents),
amlodipine was associated with an adjusted mean change
of -16.6mmHg (95% CI -18.5, -14.8) vs. -10.0mmHg
for valsartan (95% CI -12.8, -7.2; p < 0.001). Within
this subgroup, JNC VI goal attainment was 43% vs. 36%
for amlodipine vs. valsartan (p = 0.095). CONCLU-
SIONS: In monotherapy and in combination, amlodipine
demonstrated both a statistically signiﬁcant and clinically
meaningful improvements in SBP change and JNC VI goal
attainments vs. valsartan, particularly among patients on
complex antihypertensive regimens. Although these data
must be interpreted within the limitations of the obser-
vational study design, this study suggests that amlodipine
may be used in a variety of therapeutic combinations 
and among a broad spectrum of hypertensive adults to
improve SBP control and goal attainment.
METHODOLOGY ISSUES
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FOR EVENT-TIME DATA:AN EXAMPLE USING
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